메뉴 건너뛰기




Volumn 10, Issue , 2016, Pages 3685-3698

Ustekinumab in treatment of Crohn’s disease: Design, development, and potential place in therapy

Author keywords

Crohn s disease; Inflammatory bowel disease; Interleukin 12; Interleukin 12 23 monoclonal antibody; Interleukin 23; Ustekinumab

Indexed keywords

GUSELKUMAB; INTERLEUKIN 12; INTERLEUKIN 23; PLACEBO; RISANKIZUMAB; USTEKINUMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

EID: 84995684222     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S102141     Document Type: Review
Times cited : (42)

References (89)
  • 1
    • 70949107842 scopus 로고    scopus 로고
    • Inflammatory bowel disease
    • Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
    • (2009) N Engl J Med , vol.361 , Issue.21 , pp. 2066-2078
    • Abraham, C.1    Cho, J.H.2
  • 2
    • 34547176642 scopus 로고    scopus 로고
    • Unravelling the pathogenesis of inflammatory bowel disease
    • Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434.
    • (2007) Nature , vol.448 , Issue.7152 , pp. 427-434
    • Xavier, R.J.1    Podolsky, D.K.2
  • 3
    • 0028899859 scopus 로고
    • Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators
    • Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–297.
    • (1995) N Engl J Med , vol.332 , Issue.5 , pp. 292-297
    • Feagan, B.G.1    Rochon, J.2    Fedorak, R.N.3
  • 4
    • 0018888679 scopus 로고
    • Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study
    • Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302(18):981–987.
    • (1980) N Engl J Med , vol.302 , Issue.18 , pp. 981-987
    • Present, D.H.1    Korelitz, B.I.2    Wisch, N.3    Glass, J.L.4    Sachar, D.B.5    Pasternack, B.S.6
  • 5
    • 33750133513 scopus 로고    scopus 로고
    • Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication
    • Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12(35):5606–5610.
    • (2006) World J Gastroenterol , vol.12 , Issue.35 , pp. 5606-5610
    • Peluso, I.1    Pallone, F.2    Monteleone, G.3
  • 7
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
    • (2008) Lancet , vol.371 , Issue.9625 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3
  • 8
    • 43449139402 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    • Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
    • (2008) Lancet , vol.371 , Issue.9625 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3
  • 9
    • 84883134297 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    • McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
    • (2013) Lancet , vol.382 , Issue.9894 , pp. 780-789
    • McInnes, I.B.1    Kavanaugh, A.2    Gottlieb, A.B.3
  • 10
    • 84899991797 scopus 로고    scopus 로고
    • Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
    • Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
    • (2014) Ann Rheum Dis , vol.73 , Issue.6 , pp. 990-999
    • Ritchlin, C.1    Rahman, P.2    Kavanaugh, A.3
  • 11
    • 85080486639 scopus 로고    scopus 로고
    • Stelara® [package insert], Janssen Biotech, IncMarch, Accessed August 9, 2016
    • Stelara® [package insert]. Horsham, PA: Janssen Biotech, Inc.; March 2014. Available from: https://www.stelarainfo.com/pdf/prescribinginformation.pdf. Accessed August 9, 2016.
    • Horsham, P.A.1
  • 12
    • 8344284998 scopus 로고    scopus 로고
    • Anti-interleukin-12 antibody for active Crohn’s disease
    • Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–2079.
    • (2004) N Engl J Med , vol.351 , Issue.20 , pp. 2069-2079
    • Mannon, P.J.1    Fuss, I.J.2    Mayer, L.3
  • 13
    • 84871701834 scopus 로고    scopus 로고
    • Ustekinumab induction and maintenance therapy in refractory Crohn’s disease
    • Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–1528.
    • (2012) N Engl J Med , vol.367 , Issue.16 , pp. 1519-1528
    • Sandborn, W.J.1    Gasink, C.2    Gao, L.L.3
  • 14
    • 53049091561 scopus 로고    scopus 로고
    • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease
    • Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–1141.
    • (2008) Gastroenterology , vol.135 , Issue.4 , pp. 1130-1141
    • Sandborn, W.J.1    Feagan, B.G.2    Fedorak, R.N.3
  • 15
    • 85080564067 scopus 로고    scopus 로고
    • FDA Approves STELARA® (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn’s Disease. Janssen Biotech, Incpress releasePR Newswire, September 26, Accessed October 7, 2016
    • FDA Approves STELARA® (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn’s Disease. Janssen Biotech, Inc. [press release]. PR Newswire; 2016 [September 26]. Available from: http://www.prnewswire.com/news-releases/fda-approves-stelara-ustekinumab-for-treatment-of-adults-with-moderately-to-severely-active-crohns-disease-300333868.html. Accessed October 7, 2016.
    • (2016)
  • 16
    • 0037313578 scopus 로고    scopus 로고
    • Interleukin-12 and the regulation of innate resistance and adaptive immunity
    • Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–146.
    • (2003) Nat Rev Immunol , vol.3 , Issue.2 , pp. 133-146
    • Trinchieri, G.1
  • 17
    • 0024467154 scopus 로고
    • Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
    • Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170(3):827–845.
    • (1989) J Exp Med , vol.170 , Issue.3 , pp. 827-845
    • Kobayashi, M.1    Fitz, L.2    Ryan, M.3
  • 18
    • 0030445948 scopus 로고    scopus 로고
    • A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits
    • Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A. 1996;93(24):14002–14007.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , Issue.24 , pp. 14002-14007
    • Presky, D.H.1    Yang, H.2    Minetti, L.J.3
  • 19
    • 0036604306 scopus 로고    scopus 로고
    • A receptor for the heterodimeric cytokine IL-23 is composed of IL-12 Rbeta1 and a novel cytokine receptor subunit, IL-23R
    • Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12 Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–5708.
    • (2002) J Immunol , vol.168 , Issue.11 , pp. 5699-5708
    • Parham, C.1    Chirica, M.2    Timans, J.3
  • 20
    • 0037449737 scopus 로고    scopus 로고
    • Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
    • Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–1914.
    • (2003) J Biol Chem , vol.278 , Issue.3 , pp. 1910-1914
    • Aggarwal, S.1    Ghilardi, N.2    Xie, M.H.3    De Sauvage, F.J.4    Gurney, A.L.5
  • 21
    • 34548133583 scopus 로고    scopus 로고
    • Development, cytokine profile and function of human interleukin 17-producing helper T cells
    • Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950–957.
    • (2007) Nat Immunol , vol.8 , Issue.9 , pp. 950-957
    • Wilson, N.J.1    Boniface, K.2    Chan, J.R.3
  • 23
    • 79958277385 scopus 로고    scopus 로고
    • IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease
    • Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208(6):1127–1133.
    • (2011) J Exp Med , vol.208 , Issue.6 , pp. 1127-1133
    • Geremia, A.1    Arancibia-Carcamo, C.V.2    Fleming, M.P.3
  • 24
    • 79960209969 scopus 로고    scopus 로고
    • Therapeutic targeting of the IL-12/23 pathways: Generation and characterization of ustekinumab
    • Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29(7):615–624.
    • (2011) Nat Biotechnol , vol.29 , Issue.7 , pp. 615-624
    • Benson, J.M.1    Sachs, C.W.2    Treacy, G.3
  • 25
    • 0028861975 scopus 로고
    • Antibodies to interleukin 12 abrogate established experimental colitis in mice
    • Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182(5):1281–1290.
    • (1995) J Exp Med , vol.182 , Issue.5 , pp. 1281-1290
    • Neurath, M.F.1    Fuss, I.2    Kelsall, B.L.3    Stuber, E.4    Strober, W.5
  • 26
    • 33747089041 scopus 로고    scopus 로고
    • Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology
    • Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25(2):309–318.
    • (2006) Immunity , vol.25 , Issue.2 , pp. 309-318
    • Uhlig, H.H.1    McKenzie, B.S.2    Hue, S.3
  • 27
    • 33747777440 scopus 로고    scopus 로고
    • Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis
    • Becker C, Dornhoff H, Neufert C, et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 2006;177(5):2760–2764.
    • (2006) J Immunol , vol.177 , Issue.5 , pp. 2760-2764
    • Becker, C.1    Dornhoff, H.2    Neufert, C.3
  • 28
    • 79955563439 scopus 로고    scopus 로고
    • Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases
    • Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–1767.
    • (2011) Gastroenterology , vol.140 , Issue.6 , pp. 1756-1767
    • Strober, W.1    Fuss, I.J.2
  • 29
    • 84901384833 scopus 로고    scopus 로고
    • Anti-IL-12/23 in Crohn’s disease: Bench and bedside
    • Niederreiter L, Adolph TE, Kaser A. Anti-IL-12/23 in Crohn’s disease: bench and bedside. Curr Drug Targets. 2013;14(12):1379–1384.
    • (2013) Curr Drug Targets , vol.14 , Issue.12 , pp. 1379-1384
    • Niederreiter, L.1    Adolph, T.E.2    Kaser, A.3
  • 30
    • 54249138516 scopus 로고    scopus 로고
    • Monoclonal antibody pharmacokinetics and pharmacodynamics
    • Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
    • (2008) Clin Pharmacol Ther , vol.84 , Issue.5 , pp. 548-558
    • Wang, W.1    Wang, E.Q.2    Balthasar, J.P.3
  • 31
    • 85080511101 scopus 로고    scopus 로고
    • US FDA Center for Drug Evaluation and Research: Ustekinumab, Accessed July 18, 2016
    • US FDA Center for Drug Evaluation and Research: Ustekinumab (2013). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125261s086lbl.pdf. Accessed July 18, 2016.
    • (2013)
  • 32
    • 34249039292 scopus 로고    scopus 로고
    • A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis
    • Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23(5):1081–1092.
    • (2007) Curr Med Res Opin , vol.23 , Issue.5 , pp. 1081-1092
    • Gottlieb, A.B.1    Cooper, K.D.2    McCormick, T.S.3
  • 33
    • 84858793037 scopus 로고    scopus 로고
    • Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms
    • Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–646.
    • (2012) Clin Pharmacol Ther , vol.91 , Issue.4 , pp. 635-646
    • Ordas, I.1    Mould, D.R.2    Feagan, B.G.3    Sandborn, W.J.4
  • 34
    • 58849118867 scopus 로고    scopus 로고
    • Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
    • Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–175.
    • (2009) J Clin Pharmacol , vol.49 , Issue.2 , pp. 162-175
    • Zhu, Y.1    Hu, C.2    Lu, M.3
  • 35
    • 69749119482 scopus 로고    scopus 로고
    • Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies
    • Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today. 2009;14(17–18):891–898.
    • (2009) Drug Discov Today , vol.14 , Issue.17-18 , pp. 891-898
    • Zhou, H.1    Davis, H.M.2
  • 36
    • 74249094930 scopus 로고    scopus 로고
    • Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    • Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
    • (2010) N Engl J Med , vol.362 , Issue.2 , pp. 118-128
    • Griffiths, C.E.1    Strober, B.E.2    Van De Kerkhof, P.3
  • 37
    • 72049124819 scopus 로고    scopus 로고
    • Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease
    • Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease. Am J Gastroenterol. 2009;104(11):2768–2773.
    • (2009) Am J Gastroenterol , vol.104 , Issue.11 , pp. 2768-2773
    • Toedter, G.P.1    Blank, M.2    Lang, Y.3    Chen, D.4    Sandborn, W.J.5    De Villiers, W.J.6
  • 38
    • 84995563335 scopus 로고    scopus 로고
    • Ustekinumab as Induction and Maintenance Therapy for Crohn’s disease
    • Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s disease. N Engl J Med. 2016. In Press.
    • (2016) N Engl J Med
    • Feagan, B.G.1    Sandborn, W.J.2    Gasink, C.3
  • 39
    • 84984612711 scopus 로고    scopus 로고
    • O-001 A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TFNalpha: UNITI-1 (abstract)
    • Sandborn W, Gasink C, Blank M, et al. O-001 A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TFNalpha: UNITI-1 (abstract). Inflamm Bowel Dis. 2016;22(Suppl 1):S1.
    • (2016) Inflamm Bowel Dis , vol.22
    • Sandborn, W.1    Gasink, C.2    Blank, M.3
  • 40
    • 84976325622 scopus 로고    scopus 로고
    • OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naïve or not refractory to anti-TNFa: UNITI-2 (abstract)
    • Feagan B, Gasink C, Lang Y, et al. OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naïve or not refractory to anti-TNFa: UNITI-2 (abstract). United European Gastroenterol J. 2015;3(6):2.
    • (2015) United European Gastroenterol J , vol.3 , Issue.6 , pp. 2
    • Feagan, B.1    Gasink, C.2    Lang, Y.3
  • 41
    • 84992075713 scopus 로고    scopus 로고
    • 768 A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn’s disease patients: Results from IM-UNITI (abstract)
    • Sandborn W, Feagan BG, Gasink C, et al. 768 A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn’s disease patients: results from IM-UNITI (abstract). Gastroenterology. 2016;150(4):S157–S158.
    • (2016) Gastroenterology , vol.150 , Issue.4 , pp. S157-S158
    • Sandborn, W.1    Feagan, B.G.2    Gasink, C.3
  • 42
    • 84995551580 scopus 로고    scopus 로고
    • Su1420 Ustekinumab treatment for Crohn’s disease in clinical practice: Experience at a tertiary medical center
    • Batista DD, Yadav S, Harmsen WS, et al. Su1420 Ustekinumab treatment for Crohn’s disease in clinical practice: experience at a tertiary medical center (abstract). Gastroenterology. 2014;146(5):S-464–S-465.
    • (2014) Gastroenterology , vol.146 , Issue.5 , pp. 464-465
    • Batista, D.D.1    Yadav, S.2    Harmsen, W.S.3
  • 43
    • 84927796919 scopus 로고    scopus 로고
    • Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience
    • Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8(11):1516–1522.
    • (2014) J Crohns Colitis , vol.8 , Issue.11 , pp. 1516-1522
    • Kopylov, U.1    Afif, W.2    Cohen, A.3
  • 44
    • 84958932029 scopus 로고    scopus 로고
    • Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents
    • Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(2):242–250.e241–e242.
    • (2016) Clin Gastroenterol Hepatol , vol.14 , Issue.2 , pp. 242-250
    • Wils, P.1    Bouhnik, Y.2    Michetti, P.3
  • 45
    • 84976291747 scopus 로고    scopus 로고
    • Ustekinumab for the treatment of refractory Crohn’s disease: The Spanish experience in a large multicentre open-label cohort
    • Khorrami S, Ginard D, Marin-Jimenez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–1669.
    • (2016) Inflamm Bowel Dis , vol.22 , Issue.7 , pp. 1662-1669
    • Khorrami, S.1    Ginard, D.2    Marin-Jimenez, I.3
  • 46
    • 84995667923 scopus 로고    scopus 로고
    • Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: Results from the UNITI-1 and UNITI-2 studies (abstract)
    • Adedokun O, Xu Z, Gasink C, et al. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies (abstract). J Crohns Colitis. 2016;10:S23–S24.
    • (2016) J Crohns Colitis , vol.10 , pp. S23-S24
    • Adedokun, O.1    Xu, Z.2    Gasink, C.3
  • 47
    • 84995568401 scopus 로고    scopus 로고
    • Sa1934 Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn’s disease with ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI studies (abstract)
    • Adedokun OJ, Xu Z, Gasink C, et al. Sa1934 Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn’s disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies (abstract). Gastroenterology. 2016;150(4):S408.
    • (2016) Gastroenterology , vol.150 , Issue.4
    • Adedokun, O.J.1    Xu, Z.2    Gasink, C.3
  • 48
    • 85002578591 scopus 로고    scopus 로고
    • Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes (Abstract)
    • Battat R, Kopylov U, Bessissow T, et al. Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes (abstract). J Crohns Colitis. 2016;10:S74.
    • (2016) J Crohns Colitis , vol.10
    • Battat, R.1    Kopylov, U.2    Bessissow, T.3
  • 49
    • 33746534417 scopus 로고    scopus 로고
    • IL-23 promotes tumour incidence and growth
    • Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461–465.
    • (2006) Nature , vol.442 , Issue.7101 , pp. 461-465
    • Langowski, J.L.1    Zhang, X.2    Wu, L.3
  • 50
    • 0027239503 scopus 로고
    • Antitumor and antimetastatic activity of interleukin 12 against murine tumors
    • Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178(4):1223–1230.
    • (1993) J Exp Med , vol.178 , Issue.4 , pp. 1223-1230
    • Brunda, M.J.1    Luistro, L.2    Warrier, R.R.3
  • 51
    • 84881273940 scopus 로고    scopus 로고
    • Ustekinumab for the treatment of Crohn’s disease
    • Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5(8):803–815.
    • (2013) Immunotherapy , vol.5 , Issue.8 , pp. 803-815
    • Khanna, R.1    Feagan, B.G.2
  • 52
    • 84875433817 scopus 로고    scopus 로고
    • Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up
    • Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854.
    • (2013) Br J Dermatol , vol.168 , Issue.4 , pp. 844-854
    • Papp, K.A.1    Griffiths, C.E.2    Gordon, K.3
  • 53
    • 84941599682 scopus 로고    scopus 로고
    • Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
    • Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
    • (2015) J Drugs Dermatol , vol.14 , Issue.7 , pp. 706-714
    • Papp, K.1    Gottlieb, A.B.2    Naldi, L.3
  • 54
    • 13344284635 scopus 로고    scopus 로고
    • A reversible posterior leukoencephalopathy syndrome
    • Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.
    • (1996) N Engl J Med , vol.334 , Issue.8 , pp. 494-500
    • Hinchey, J.1    Chaves, C.2    Appignani, B.3
  • 55
    • 80054734943 scopus 로고    scopus 로고
    • Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: Case report and review of the literature
    • Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol. 2011;147(10):1197–1202.
    • (2011) Arch Dermatol , vol.147 , Issue.10 , pp. 1197-1202
    • Gratton, D.1    Szapary, P.2    Goyal, K.3    Fakharzadeh, S.4    Germain, V.5    Saltiel, P.6
  • 56
    • 84995633150 scopus 로고    scopus 로고
    • Mo1884 prevalence of inflammatory bowel disease among patients with psoriasis and incidence of serious infections in this subset: Results from the PSOLAR registry (abstract)
    • Loftus EV, Augustin M, Bissonnette R, et al. Mo1884 prevalence of inflammatory bowel disease among patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR registry (abstract). Gastroenterology. 2016;150(4):S805.
    • (2016) Gastroenterology , vol.150 , Issue.4
    • Loftus, E.V.1    Augustin, M.2    Bissonnette, R.3
  • 57
    • 80052074383 scopus 로고    scopus 로고
    • Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials
    • Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–871.
    • (2011) JAMA , vol.306 , Issue.8 , pp. 864-871
    • Ryan, C.1    Leonardi, C.L.2    Krueger, J.G.3
  • 58
    • 84906790420 scopus 로고    scopus 로고
    • Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease
    • Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease. J Crohns Colitis. 2014;8(9):1138–1139.
    • (2014) J Crohns Colitis , vol.8 , Issue.9 , pp. 1138-1139
    • Badat, Y.1    Meissner, W.G.2    Laharie, D.3
  • 59
    • 84964660329 scopus 로고    scopus 로고
    • Use of immunomodulators and biologics before, during, and after pregnancy
    • McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. Inflamm Bowel Dis. 2016;22(1):213–223.
    • (2016) Inflamm Bowel Dis , vol.22 , Issue.1 , pp. 213-223
    • McConnell, R.A.1    Mahadevan, U.2
  • 60
    • 78650498507 scopus 로고    scopus 로고
    • Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation
    • Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):351–363.
    • (2010) Birth Defects Res B Dev Reprod Toxicol , vol.89 , Issue.5 , pp. 351-363
    • Martin, P.L.1    Sachs, C.2    Imai, N.3
  • 61
    • 84977162841 scopus 로고    scopus 로고
    • Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program
    • Schaufelberg BW, Horn E, Cather J, Rahawi K. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program (abstract). J Am Acad Dermatol. 2014;70(5):AB178.
    • (2014) J am Acad Dermatol , vol.70 , Issue.5
    • Schaufelberg, B.W.1    Horn, E.2    Cather, J.3    Rahawi, K.4
  • 62
    • 84995668306 scopus 로고    scopus 로고
    • 437 Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry
    • Mahadevan U, Martin C, Kane SV, Dubinsky M, Sands BE, Sandborn W. 437 Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry (abstract). Gastroenterology. 2016;150(4):S91–S92.
    • (2016) Gastroenterology , vol.150 , Issue.4 , pp. S91-S92
    • Mahadevan, U.1    Martin, C.2    Kane, S.V.3    Dubinsky, M.4    Sands, B.E.5    Sandborn, W.6
  • 63
    • 84959220441 scopus 로고    scopus 로고
    • The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy
    • Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734–757.e731.
    • (2016) Gastroenterology , vol.150 , Issue.3 , pp. 734-757
    • Nguyen, G.C.1    Seow, C.H.2    Maxwell, C.3
  • 64
    • 84941887963 scopus 로고    scopus 로고
    • Update on the medical management of Crohn’s disease
    • Deepak P, Bruining DH. Update on the medical management of Crohn’s disease. Curr Gastroenterol Rep. 2015;17(11):41.
    • (2015) Curr Gastroenterol Rep , vol.17 , Issue.11 , pp. 41
    • Deepak, P.1    Bruining, D.H.2
  • 65
    • 84888221077 scopus 로고    scopus 로고
    • American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease
    • Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145(6):1459–1463.
    • (2013) Gastroenterology , vol.145 , Issue.6 , pp. 1459-1463
    • Terdiman, J.P.1    Gruss, C.B.2    Heidelbaugh, J.J.3    Sultan, S.4    Falck-Ytter, Y.T.5
  • 66
    • 84951906995 scopus 로고    scopus 로고
    • Systematic review: Predicting and optimising response to anti-TNF therapy in Crohn’s disease – algorithm for practical management
    • Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease – algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.
    • (2016) Aliment Pharmacol Ther , vol.43 , Issue.1 , pp. 30-51
    • Ding, N.S.1    Hart, A.2    De Cruz, P.3
  • 67
    • 79953688705 scopus 로고    scopus 로고
    • Review article: Loss of response to anti-TNF treatments in Crohn’s disease
    • Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
    • (2011) Aliment Pharmacol Ther , vol.33 , Issue.9 , pp. 987-995
    • Ben-Horin, S.1    Chowers, Y.2
  • 68
    • 79953786419 scopus 로고    scopus 로고
    • Loss of response and need for adalimumab dose intensification in Crohn’s disease: A systematic review
    • Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674–684.
    • (2011) Am J Gastroenterol , vol.106 , Issue.4 , pp. 674-684
    • Billioud, V.1    Sandborn, W.J.2    Peyrin-Biroulet, L.3
  • 69
    • 84906569062 scopus 로고    scopus 로고
    • Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed
    • Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e613.
    • (2014) Gastroenterology , vol.147 , Issue.3 , pp. 618-627
    • Sands, B.E.1    Feagan, B.G.2    Rutgeerts, P.3
  • 70
    • 84882749768 scopus 로고    scopus 로고
    • Vedolizumab as induction and maintenance therapy for Crohn’s disease
    • Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
    • (2013) N Engl J Med , vol.369 , Issue.8 , pp. 711-721
    • Sandborn, W.J.1    Feagan, B.G.2    Rutgeerts, P.3
  • 72
    • 84943663241 scopus 로고    scopus 로고
    • Review article: Pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
    • Papamichael K, Van Stappen T, Jairath V, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42(10):1158–1169.
    • (2015) Aliment Pharmacol Ther , vol.42 , Issue.10 , pp. 1158-1169
    • Papamichael, K.1    Van Stappen, T.2    Jairath, V.3
  • 73
    • 84895424744 scopus 로고    scopus 로고
    • Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
    • Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–577.
    • (2014) Gut , vol.63 , Issue.4 , pp. 567-577
    • Tillack, C.1    Ehmann, L.M.2    Friedrich, M.3
  • 74
    • 84939266240 scopus 로고    scopus 로고
    • Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: A 14-year experience
    • Freling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186–1196.
    • (2015) Am J Gastroenterol , vol.110 , Issue.8 , pp. 1186-1196
    • Freling, E.1    Baumann, C.2    Cuny, J.F.3
  • 75
    • 84962288522 scopus 로고    scopus 로고
    • Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: A nationwide cohort study
    • Guerra I, Perez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.
    • (2016) Inflamm Bowel Dis , vol.22 , Issue.4 , pp. 894-901
    • Guerra, I.1    Perez-Jeldres, T.2    Iborra, M.3
  • 77
    • 84872683372 scopus 로고    scopus 로고
    • Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab
    • Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67(5):e237–e238.
    • (2012) J am Acad Dermatol , vol.67 , Issue.5
    • Goldminz, A.M.1    Botto, N.C.2    Gottlieb, A.B.3
  • 78
    • 80054754826 scopus 로고    scopus 로고
    • Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab
    • Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–1205.
    • (2011) Arch Dermatol , vol.147 , Issue.10 , pp. 1203-1205
    • Guenova, E.1    Teske, A.2    Fehrenbacher, B.3
  • 79
    • 84902378517 scopus 로고    scopus 로고
    • Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: Preliminary results
    • Gheita TA, El G II, El-Fishawy HS, Aboul-Ezz MA, Kenawy SA. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin Rheumatol. 2014;33(5):713–717.
    • (2014) Clin Rheumatol , vol.33 , Issue.5 , pp. 713-717
    • Gheita, T.A.1    El, G.2    El-Fishawy, H.S.3    Aboul-Ezz, M.A.4    Kenawy, S.A.5
  • 80
    • 84894082076 scopus 로고    scopus 로고
    • Specific targeting of interleukin-23p19 as effective treatment for psoriasis
    • Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555–561.
    • (2014) J am Acad Dermatol , vol.70 , Issue.3 , pp. 555-561
    • Levin, A.A.1    Gottlieb, A.B.2
  • 81
    • 84961792836 scopus 로고    scopus 로고
    • A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis
    • Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther. 2016;6(1):1–12.
    • (2016) Dermatol Ther , vol.6 , Issue.1 , pp. 1-12
    • Campa, M.1    Mansouri, B.2    Warren, R.3    Menter, A.4
  • 83
    • 84991675498 scopus 로고    scopus 로고
    • Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis
    • Accessed October 9, 2016
    • Papp K, Menter A, Sofen H, et al. Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis (abstract). Arthritis Rheumatol. 2015;67(Suppl 10). Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-different-dose-regimens-of-a-selective-il-23p19-inhibitor-bi-655066-compared-with-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-with-and-without-psoriatic-a/. Accessed October 9, 2016.
    • (2015) Arthritis Rheumatol
    • Papp, K.1    Menter, A.2    Sofen, H.3
  • 84
    • 85080504806 scopus 로고    scopus 로고
    • Janssen Research & Development, LLC, Bethesda (MD): National Library of Medicine (US), cited 2016 Oct 7NLMIdentifier: NCT02203032, Accessed October 7, 2016
    • Janssen Research & Development, LLC. A study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab (NAVIGATE). Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Oct 7]. NLM Identifier: NCT02203032. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02203032. Accessed October 7, 2016.
    • (2000) A Study of Guselkumab in Participants with Moderate to Severe Plaque-Type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)
  • 85
    • 84995682586 scopus 로고    scopus 로고
    • 830 Initial evaluation of MEDI2070 (Specific anti-IL-23 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: A randomized, double-blind placebo-controlled phase 2A induction study
    • Sands BE, Chen J, Penney M, et al. 830 Initial evaluation of MEDI2070 (specific anti-IL-23 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: a randomized, double-blind placebo-controlled phase 2A induction study (abstract). Gastroenterology. 2015;148(4):S-163–S-164.
    • (2015) Gastroenterology , vol.148 , Issue.4 , pp. 163-164
    • Sands, B.E.1    Chen, J.2    Penney, M.3
  • 86
    • 84995691457 scopus 로고    scopus 로고
    • 812a Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn’s disease: Results of a randomized, double-blind, placebo-controlled phase II study
    • Feagan BG, Sandborn W, Panés J, et al. 812a Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn’s disease: results of a randomized, double-blind, placebo-controlled phase II study (abstract). Gastroenterology. 2016;150(4):S1266.
    • (2016) Gastroenterology , vol.150 , Issue.4
    • Feagan, B.G.1    Sandborn, W.2    Panés, J.3
  • 87
    • 84995682599 scopus 로고    scopus 로고
    • Sun Pharma and Merck & Co. Inc, Merck & Co., Inc. [press release]. Merck Sharp & Dohme Corp. websiteSeptember 17, Accessed October 7, 2016
    • Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab, Merck & Co., Inc. [press release]. Merck Sharp & Dohme Corp. website; 2014 [September 17]. Available from: http://www.merck.com/licensing/our-partnership/sunpharma_partnership.html. Accessed October 7, 2016.
    • Enter into Licensing Agreement for Tildrakizumab
  • 88
    • 84978399780 scopus 로고    scopus 로고
    • The present and future of inflammatory bowel disease treatment
    • Sandborn WJ. The present and future of inflammatory bowel disease treatment. Gastroenterol Hepatol. 2016;12(7):438–441.
    • (2016) Gastroenterol Hepatol , vol.12 , Issue.7 , pp. 438-441
    • Sandborn, W.J.1
  • 89
    • 84995595066 scopus 로고    scopus 로고
    • Serum soluble IL2-receptor is increased in a subpopulation of Crohns disease patients, who respond to open label use of ustekinumab, a human monoclonal antibody to IL-12/23p40
    • Kuehbacher T, Nikolaus S, Schreiber S. Serum soluble IL2-receptor is increased in a subpopulation of Crohns disease patients, who respond to open label use of ustekinumab, a human monoclonal antibody to IL-12/23p40 (abstract). Gastroenterology. 2011;140(5):S-589.
    • (2011) Gastroenterology , vol.140 , Issue.5
    • Kuehbacher, T.1    Nikolaus, S.2    Schreiber, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.